NEW YORK (GenomeWeb News) – Dimerix Bioscience said today that it will help Takeda Cambridge Limited study G-protein coupled receptors (GPCR) that Takeda believes may be developed into drug compounds.
Under the agreement, Australia-based Dimerix will use its GPCR-HIT platform to form complexes called heteromers that can be used to screen for and profile compounds for Takeda Cambridge, which is a UK-based subsidiary of Japan's Takeda Pharmaceutical.
"Dimerix' GPCR-HIT platform enables the development of more specific drugs that take into account the signaling profile of GPCRs acting in heteromeric complexes," Dimerix CEO Tim Grogan said in a statement.
The GPCR-HIT technology, which Dimerix acquired from its developers at the University of Western Australia, can expand the scope of GPCR drug discovery efforts by identifying compounds with signaling that is mediated through GPCR heteromers.
Financial terms of the agreement were not released.